Revolutionary cancer therapy: Menarini secures groundbreaking license!

Revolutionary cancer therapy: Menarini secures groundbreaking license!

Laimgrubengasse 10, 1060 Wien, Österreich - The Menarini Group has announced a groundbreaking development in the field of oncology. In an exclusive agreement with Insilico Medicine, a company that specializes in generative artificial intelligence, Menarini has achieved global rights to develop a promising low -molecular active ingredient. This aims at a variety of solid tumors and could offer new therapy options for cancer patients. Loud Menarini If the contract will include an advance payment of $ 20 million, the total value of the agreement is over $ 550 million, including further payment terms.

innovative cancer therapies in view of

This new active ingredient is based on the advanced technologies of Insilico, which enable medication to develop with the help of generative AI. He has shown impressive anti-tumor activity in preclinical studies. "We are enthusiastic about this second collaboration with Insilico Medicine," said Elcin Barker Ergun, CEO of the Menarini Group. "This active ingredient will help us to penetrate areas with strong, uncovered needs and create new treatment options for cancer patients," he added. This is not the first time that Menarini and Insilico work together; As early as January 2024, a similar license agreement for the promising active ingredient Men2312 was also concluded, which also progresses into the clinical phase.

The Menarini Group is an international pharmaceutical company with annual sales of over $ 4.7 billion and over $ 17,000. The company focuses on areas with high unexpected needs, especially in oncology, pneumology and diabetology. Insilico Medicine, on the other hand, uses AI technologies to develop innovative solutions for drug discovery. This collaboration could not only significantly improve the treatment of cancer, but also represent a new approach for drug development, such as according to a report by OTS